IGF-1R, insulin-like growth factor-1 receptor.

Treats a root cause of TED

TEPEZZA is designed to target and block IGF-1R, a key driver of TED
pathophysiology1-4

Rapid response

Proptosis reduction was seen as soon as Week 6 in some patients and continued through Week 241,3*

Demonstrated safety profile

9 of 10 patients completed the full treatment course of TEPEZZA1,5†

*In Phase 2 and 3 studies (N=83).1

†In Phase 2 and 3 studies (N=84) and Phase 4 study (N=41).1,5

TED is a serious, progressive disease that can present with a variety of signs and symptoms and may impact daily activities and emotional well-being.

Meet several patients below as they take you on their journey with TEPEZZA. You can also experience TED through the eyes of a patient with the TED Burden Simulator.

MEET BONNIE

Explore Bonnie’s transformation on TEPEZZA

baselinebaseline

My name is Bonnie, and I was diagnosed with Thyroid Eye Disease in August of 2020. After trying steroids and not having any results in the reduction of my symptoms, my doctor and I decided that TEPEZZA was the best option for me.

Select Important Safety Information

TEPEZZA should not be used in pregnancy, and appropriate forms of contraception should be implemented prior to initiation, during treatment and for 6 months following the last dose of TEPEZZA. If the patient becomes pregnant during treatment, TEPEZZA should be discontinued and the patient advised of the potential risk to the fetus.

Infusion 1 Infusion 1

Infusion 2Infusion 2

I can already see some of the swelling has gone down. My double vision is actually getting better as well.

Infusion 3Infusion 3

Infusion 4Infusion 4

I went to the doctor last week, and I had a reduction of about 4 mm on my left eye for bulging and 2 mm on my right eye.

Infusion 5Infusion 5

Infusion 6Infusion 6

I’m feeling great and really seeing wonderful results. I definitely feel like my eye bulging has gone down significantly. And after this infusion, I do feel like my eyelids have come down some, too. Now the double vision is almost completely gone.

Infusion 7Infusion 7

I’m really excited with the results I’ve seen. I’m definitely still seeing a reduction of eye bulging, and I feel like I have more eye movement—peripheral and up and down.

Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image

I can definitely tell a huge difference in where I started versus where I am now. I feel like I am looking more and more like myself every single day, I am thankful for this opportunity and the advances in science and medicine to be able to take TEPEZZA.

SEE PATIENTS RESULTS

TEPEZZA has been shown to be effective in patients with TED with a wide range of clinical manifestations1,3,6,7

Because each patient responds differently to treatment, it is important that patients complete the full TEPEZZA treatment course of 8 IV infusions as studied in clinical trials1
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
Baseline and infusion image
EXPERIENCE TED
BURDEN

Experience the burden of TED

See the world through the eyes of patients living with the burden of TED by engaging in 3 patient-inspired challenges.

EXPERIENCE TED HERE

For those with an Android device, you can also download the Google VR Services app at the Google Play app store and pair your phone with a virtual reality (VR) headset. Ensure your volume is turned on.

Experience the burden of TED

Modal

For those with an Android device, you can also download the Google VR Services app at the Google Play app store and pair your phone with a virtual reality (VR) headset. Ensure your volume is turned on.

What’s next?

Thyroid Eye Disease (TED) can be a vision-threatening autoimmune
disease, and its symptoms are not always obvious.8-10

Are you ready to
take action?

Do you treat patients with TED?
Yes,
I treat patients with TEPEZZA.
Rotate Now icon
Click to rotate

We appreciate the important part you play in your patients’ treatment of TED.

Learn how TEPEZZA can help patients with TED regardless of disease activity or duration.1

No,
but I would like to learn how.
Rotate Now icon
Click to rotate

Thank you for taking the first step in helping patients on their unique TED journey. To get your patients started on TEPEZZA, contact a Horizon Representative now.

A Horizon Representative will educate you every step of the way.

No,
I refer, or want to refer my patients to a TED Specialist for treatment.
Rotate Now icon
Click to rotate

Consulting with a TED Specialist is an important part of co-managing TED, and your referrals play an important role in reducing the burden of TED.11,12

Find a TED Specialist for your patients.

Having trouble finding a specialist in your area? Check back regularly. We are constantly updating and adding TED Specialists.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.

INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

Hearing Impairment Including Hearing Loss: TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients’ hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

Please see Full Prescribing Information or visit TEPEZZAhcp.com for more information.

  1. TEPEZZA (teprotumumab-trbw) [prescribing information] Horizon.
  2. Patel A, Yang H, Douglas RS. A new era in the treatment of thyroid eye disease. Am J Ophthalmol. 2019;208:281-288.
  3. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
  4. Douglas RS. Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis. Eye (Lond). 2019;33(2):183-190.
  5. Douglas RS, Couch S, Wester ST, et al. A randomized, quadruple-masked, placebo-controlled, multicenter trial to evaluate the efficacy and safety of teprotumumab in patients with chronic (inactive/low CAS) thyroid eye disease. Presented at: ENDO 2023; June 15-18, 2023; Chicago, IL. Poster SAT-459.
  6. Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37(6):583-591.
  7. Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2022;36(8):1553-1559.
  8. Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305-1318.
  9. Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B. The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol. 2009;161(3):483-487.
  10. Konuk O, Anagnostis P. Diagnosis and differential diagnosis of Graves’ orbitopathy. In: Wiersinga WM, Kahaly GJ, eds. Graves’ Orbitopathy: A Multidisciplinary Approach - Questions and Answers. 3rd ed. S Karger AG; 2017:74-92.
  11. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
  12. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125.